Scleral Postn Drives Myopia via Promoting Myofibroblast Transdifferentiation
Investigative Ophthalmology & Visual Science · 2026
DOI: 10.1167/iovs.67.10.46 ↗Kurz gefasst
Fachartikel in der Zeitschrift Investigative Ophthalmology & Visual Science, 2026. Verfasst von Xiaolei Lin und 15 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Eye Health, Oujiang Laboratory (Zhejiang Lab for Regenerative Medicine, Vision and Brain Health), Eye Hospital, Wenzhou Medic…. Hauptthemen laut MEDLINE: Periostin, Sclera, Myopia, Myofibroblasts. Die Arbeit nennt 61 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Purpose
We previously found that scleral hypoxia led to a cascade involving glycolysis-lactate-histone H3 lysine 18 lactylation (H3K18la), which contributes to myopia. Since Cut&Tag identified Postn as a primary H3K18la-enriched extracellular matrix (ECM) gene, which encodes the periostin (Postn) protein, this study aimed to investigate whether Postn drives myopia by modulating scleral ECM remodeling.
Methods
H3K18la enrichment at the Postn promoter was validated via CUT&Tag-quantitative PCR. Scleral Postn levels were assessed via reverse-transcription quantitative PCR (RT-qPCR) and immunoblotting during form deprivation myopia (FDM) in mice. Gain- or loss-of-function experiments were conducted to evaluate the role of scleral Postn in normal refractive development or FDM. Mechanisms were explored in FDM mice and human scleral fibroblasts (HSFs) using immunoblotting, co-immunoprecipitation, gene manipulation, and recombinant human POSTN (rhPOSTN) protein treatment.
Results
H3K18la enrichment in the Postn promoter region and Postn mRNA and protein levels were increased during myopia. In HSFs, POSTN knockdown inhibited the hypoxia- or lactate-induced rise in fibroblast-to-myofibroblast transdifferentiation (FMT) and rescued type I collagen decline. Scleral Postn overexpression induced myopia in mice, while its knockdown attenuated FDM development. Mechanistically, Postn binds to integrin αvβ3 and αvβ5 receptors to activate the AKT signaling pathway, driving FMT and suppressing type I collagen.
Conclusions
Scleral Postn contributes to myopia by promoting FMT in the sclera.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- State Key Laboratory of Eye Health, Oujiang Laboratory (Zhejiang Lab for Regenerative Medicine, Vision and Brain Health), Eye Hospital, Wenzhou Medical University, Wenzhou, China.
- Research Unit of Myopia Basic Research and Clinical Prevention and Control, Chinese Academy of Medical Sciences (2019RU025), Wenzhou, Zhejiang, China.
- Key Laboratory of Biomechanics and Mechanobiology (Ministry of Education), Key Laboratory of Innovation and Transformation of Advanced Medical Devices (Ministry of Industry and Information Technology), National Medical…
- Department of Ophthalmology, State Key Laboratory of Eye Health, Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Zitieren
APA
Lin, X., Li, Y., Pan, Y., Shao, Y., Qin, L., Lei, Y., Zhong, L., Zhu, X., Li, W., Chen, W., Jiao, S., Zhai, Y., Fan, X., Qu, J., Zhou, X., & Zhao, F. (2026). Scleral Postn Drives Myopia via Promoting Myofibroblast Transdifferentiation. Investigative Ophthalmology & Visual Science. https://doi.org/10.1167/iovs.67.10.46
Vancouver
Lin X, Li Y, Pan Y, Shao Y, Qin L, Lei Y, et al. Scleral Postn Drives Myopia via Promoting Myofibroblast Transdifferentiation. Investigative Ophthalmology & Visual Science. 2026. doi:10.1167/iovs.67.10.46
BibTeX
@article{Lin2026,
author = {Lin, Xiaolei and Li, Yating and Pan, Yulu and Shao, Yaxin and Qin, Lu and Lei, Yi and Zhong, Lurong and Zhu, Xiaolong and Li, Wenjie and Chen, Wei and Jiao, Shiming and Zhai, Ying and Fan, Xianqun and Qu, Jia and Zhou, Xiangtian and Zhao, Fei},
title = {Scleral Postn Drives Myopia via Promoting Myofibroblast Transdifferentiation},
journal = {Investigative Ophthalmology & Visual Science},
year = {2026},
doi = {10.1167/iovs.67.10.46}
}
EUVIMED